Prestige Consumer Healthcare Inc. · NYSE:PBH
Prestige Consumer Healthcare — Q2 2025 Earnings Presentation
17 slides from Prestige Consumer Healthcare's earnings presentation, Nov 7, 2024
Slide 1: Second Quarter FY 2025 Results
Second Quarter FY 2025 Results November 7th, 2024
Slide 2: Safe Harbor Disclosure
Safe Harbor Disclosure This presentation contains certain “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding the Company’s expected financial performance, including revenues, organic revenue growth, adjusted diluted E
Slide 3: Agenda for Today's Discussion
Agenda for Today’s Discussion I. Performance Update II. Financial Overview III. FY 25 Outlook SECOND QUARTER FY 25 RESULTS 3
Slide 4: I. Performance Update
I. Performance Update SECOND QUARTER FY 25 RESULTS
Slide 5: Strong Results in Second Quarter FY 25
Strong Results in Second Quarter FY 25 ◼ Quarterly Revenue of $283.8 million, ahead of expectations Q2 FY 25 Sales ◼ Outperformance highlighted by strong International growth Drivers ◼ Continue to execute proven brand-building strategy ◼ Gross Margin performance stable Superior Earnings ◼ Adjusted D
Slide 6: Canada: Time-Tested Branded Leadership Driving Growth
Canada: Time-Tested Branded Leadership Driving Growth Continued Long-Term Revenue Growth* Multiple +4% CAGR Market Leading Brands +9% YTD New! Proven Success in Marketing & Innovation FY 20 FY 24 1H 24 1H 25 Brand Building Strategy At Work Enabling Robust Long-Term Growth * in constant CAD SECOND QU
Slide 7: II. Financial Overview
II. Financial Overview SECOND QUARTER FY 25 RESULTS
Slide 8: Second Quarter and 1H FY 25 Performance Highlights
Second Quarter and 1H FY 25 Performance Highlights FY 25 FY 24 Revenues of $283.8 million, down 0.8% versus (0.9%) record prior year excluding FX $283.8 $286.3 (4.0%) Q2 1.7% $91.9 $95.7 $1.09 $1.07 (2) Revenues EBITDA Diluted EPS EBITDA(2) of $91.9 million down 4.0% versus prior year due mainly to
Slide 9: FY 25 Second Quarter and 1H Consolidated Financial Summary
FY 25 Second Quarter and 1H Consolidated Financial Summary 3 Months Ended 6 Months Ended 1H Comments ◼ Organic Revenue(1) down 2.5% vs. prior year – Clear Eyes sales similar to expectations – International segment up 4.8% excluding currency – Women’s Health category performance improving sequentiall
Slide 10: Industry Leading Free Cash Flow Trends
Industry Leading Free Cash Flow Trends Free Cash Flow(2) Comments Q2 FY 25 Q2 FY 24 1H FY 25 1H FY 24 ◼ Total 1H Free Cash Flow(2) of $121.4 million up 14% vs. prior year $121.4 – Maintaining full-year free cash flow outlook(5) of $240 million or more $106.1 – Strong business attributes continue to
Slide 11: III. FY 25 Outlook
III. FY 25 Outlook SECOND QUARTER FY 25 RESULTS
Slide 12: FY 25 Outlook Unchanged
FY 25 Outlook Unchanged ◼ Remain well-positioned in dynamic macro environment ◼ Continue to emphasize brand-building on leading brands Top Line Trends ◼ Revenues of $1,125 to $1,140 million — Organic growth of approximately 1% ex-FX ◼ Adjusted Diluted EPS(4) of $4.40 to $4.46 EPS ◼ Expect earnings g
Slide 13: Q&A
Q&A SECOND QUARTER FY 25 RESULTS
Slide 14: Appendix
Appendix (1) Organic Revenue is a Non-GAAP financial measure and is reconciled to the most closely related GAAP financial measures in the attached Reconciliation Schedules and / or our earnings release dated November 7, 2024 in the “About Non-GAAP Financial Measures” section. (2) EBITDA & EBITDA Mar
Slide 15: Reconciliation Schedules
Reconciliation Schedules Organic Revenue Change Three Months Ended September 30, Six Months Ended September 30, 2024 2023 2024 2023 (In Thousands) GAAP Total Revenues $ 283,785 $ 286,316 $ 550,927 $ 565,625 Revenue Change (0.9%) (2.6%) Adjustments: Impact of foreign currency exchange rates - (165) -
Slide 16: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Adjusted Diluted EPS Three Months Ended September 30, Six Months Ended September 30, 2024 2023 2024 2023 Net Income Diluted EPS Net Income Diluted EPS Net Income Diluted EPS Net Income Diluted EPS (In Thousands, except per share data) GAAP Net Income and Diluted
Slide 17: Reconciliation Schedules (Continued)
Reconciliation Schedules (Continued) Projected Adjusted Diluted EPS Low High Projected FY'25 GAAP Diluted EPS $ 4.48 $ 4.54 Adjustments: Normalized Tax Rate Adjustment(a) (0.08) (0.08) Total Adjustments (0.08) (0.08) Projected FY'25 Non-GAAP Adjusted Diluted EPS $ 4.40 $ 4.46 (a) Income tax adjustme
Prestige Consumer Healthcare — Q2 2025 Earnings Presentation on 6ix